At a glance
ClinicalIndex Comparison RecordN/ACompleted· 199 enrolled
Drug / intervention
HDR brachytherapy as monotherapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HDR Brachytherapy Used as Monotherapy for Low and Intermediate Risk Prostate Cancer: a Phase II Randomized Trial
In Brief
A clinical study evaluating HDR brachytherapy as monotherapy for Prostate Cancer. Completed, enrolled 199 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate High-dose rate (HDR) brachytherapy (1 vs 2 fractions on single implant) as monotherapy for the treatment of low risk and intermediate risk prostate cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedFeb 2018
Primary CompletionJun 2019
Study CompletionFeb 2022
TodayJul 2026
First PostedFeb 7, 2018
Enrollment StartJun 22, 2015
Primary CompletionJun 22, 2019
Study CompletionFeb 22, 2022
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 8.4 years ago
Interventions
HDR brachytherapy as monotherapyradiation